Table 2

Supplementary information on patients by leading ACHD diagnosis

NYHA
ACHD groupnAge
(years)
Male gender
n (%)
I (%)II (%)≥III (%)Follow-up (years)
Aortic coarctation26629.6 (21.7 to 41.0)150 (56.4%)85.6013.401.006.7 (3.5 to 10.7)
Atrial septal defect47944.0 (31.1 to 58.6)181 (37.8%)63.0033.004.005.9 (4.0 to 9.0)
Atrioventricular septal defect11337.5 (25.9 to 49.0)47 (41.6%)59.8036.104.106.8 (3.7 to 9.7)
CCTGA6335.7 (24.6 to 45.2)32 (50.8%)43.8035.4020.805.6 (2.7 to 8.8)
Complex ACHD17229.0 (22.5 to 37.6)83 (48.3%)29.0060.7010.305.5 (2.9 to 9.7)
Ebstein anomaly8640.2 (29.3 to 49.9)42 (48.8%)48.4040.3011.305.1 (3.2 to 7.6)
Eisenmenger syndrome25933.6 (25.7 to 42.4)96 (37.1%)4.8057.2038.006.1 (3.2 to 9.0)
Fontan palliation11024.1 (20.0 to 31.9)55 (50.0%)44.1052.703.206.7 (3.8 to 10.8)
Other ACHD26129.7 (21.2 to 40.8)148 (56.7%)72.4023.104.504.8 (2.9 to 9.0)
Postatrial switch for TGA8528.9 (22.9 to 32.6)43 (50.6%)64.8032.402.806.4 (3.5 to 12.1)
Tetralogy of Fallot47430.8 (22.2 to 40.8)263 (55.5%)62.6034.403.005.4 (3.3 to 9.9)
Valve/outflow disease51836.4 (25.1 to 48.3)305 (58.9%)67.6026.805.605.3 (3.4 to 9.3)
Total288633.3 (23.6 to 44.7)1445 (50.1%)57.1034.908.005.7 (3.3 to 9.6)
  • The ‘Complex ACHD’ subgroup includes single-ventricle physiology patients without evidence of pulmonary hypertension. Patients classified as ‘other ACHD’ are patients with restrictive ventricular septal defects, repaired persistent ductus arteriosus, Marfan syndrome or patients with TGA after arterial switch.

  • ACHD, adult congenital heart disease; CCTGA, congenitally corrected transposition of the great arteries; NYHA, New York Heart Association; TGA, transposition of the great arteries.